Trial Profile
A Double-Blind, Double-Dummy, Randomized, Moxifloxacin and Placebo Controlled, Four-Way Crossover Study of the Effects of a Single Intravenous Supra-Therapeutic Dose and Single Intravenous Therapeutic Dose of CXA-101/Tazobactam on the QT/QTC Intervals in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary) ; Moxifloxacin
- Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors Cubist Pharmaceuticals
- 30 Jul 2015 New trial record